[ET Net News Agency, 21 May 2018] Shanghai Pharmaceuticals (02607) said it agreed to
purchase the entire equity interest in Takeda Chromo Beteiligungs AG so that it would
indirectly hold 26.34% equity interest in Techpool Bio-pharma Co., Ltd, at a total of
US$144 million (equivalent to about Rmb915 million).
Upon completion, the shareholding in Techpool by Shanghai Pharmaceuticals will be
increased from 40.8% to 67.14% and Shanghai Pharmaceuticals would achieve absolute control
of Techpool.
Techpool has a competitive advantage in natural bio-protein field, and possesses several
products with substantial market potential such as Tianpuan and Kailikang. The
incorporation of Tianpuan and Kailikang will fill the product shortage of Shanghai
Pharmaceuticals in natural bio-protein field and subdivision field of critical illness,
enriching the sales of over-billion product line and enhancing the industrial core
competitiveness. (HL)